BiotechTube

setrusumab

Phase 3Active
0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Osteogenesis Imperfecta

Conditions

Osteogenesis Imperfecta

Trial Timeline

Oct 25, 2024 → Jan 1, 2028

NCT ID
NCT06636071

About setrusumab

setrusumab is a phase 3 stage product being developed by Ultragenyx Pharmaceutical for Osteogenesis Imperfecta. The current trial status is active. This product is registered under clinical trial identifier NCT06636071. Target conditions include Osteogenesis Imperfecta.

What happened to similar drugs?

1 of 6 similar drugs in Osteogenesis Imperfecta were approved

Approved (1) Terminated (2) Active (3)
✅Teriparatide (FORTEO) + PlacebosEli LillyApproved
🔄Zoledronic AcidNovartisPhase 3
🔄Romosozumab + BisphosphonateAmgenPhase 3
❌DenosumabAmgenPhase 3
❌Denosumab + Alternative osteoporosis medicationsAmgenPhase 3
🔄Bisphosphonate + SetrusumabUltragenyx PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT06636071Phase 3Active
NCT05312697Phase 2Terminated
NCT05125809Phase 2/3Active

Competing Products

16 competing products in Osteogenesis Imperfecta

See all competitors
ProductCompanyStageHype Score
Teriparatide (FORTEO) + PlacebosEli LillyApproved
43
Zoledronic AcidNovartisPhase 2
35
Zoledronic AcidNovartisPhase 2
35
Zoledronic AcidNovartisPhase 3
40
Romosozumab + BisphosphonateAmgenPhase 3
47
RomosozumabAmgenPhase 1
29
DenosumabAmgenPhase 3
32
Denosumab + Alternative osteoporosis medicationsAmgenPhase 3
32
FresolimumabSanofiPhase 1
29
SAR439459 + PlaceboSanofiPhase 1
21
BPS804Ultragenyx PharmaceuticalPhase 2
29
SetrusumabUltragenyx PharmaceuticalPhase 2/3
36
SetrusumabUltragenyx PharmaceuticalPhase 2
21
BPS804Ultragenyx PharmaceuticalPhase 2
21
setrusumab + zoledronic acid (optional)Ultragenyx PharmaceuticalPhase 2
29
Bisphosphonate + SetrusumabUltragenyx PharmaceuticalPhase 3
38